MEDICAL THERAPY OF BENIGN PROSTATIC HYPERTROPHY

良性前列腺肥大的药物治疗

• 批准号: 6276968
• 负责人: HERBERT LEPOR
• 金额: $ 2.03万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6276968
• 关键词: antihypertensive agents; benign prostate hyperplasia; biomarker; clinical research; clinical trials; drug screening /evaluation; finasteride; human subject; human therapy evaluation; pathologic process; ultrasonography

The primary objective is to ascertain if medical therapy with finasteride and or doxazocin delays or prevents the progression of BPH. Secondary objectives will include assessment of the natural history of BPH, maximal uroflow, symptom scores and medical outcomes. A subgroup of patients will undergo ultrasound, prostate biopsy, and serum hormonal determination in order to determine the histopathology of BPH and test existing biomarkers for their prognostic ability regarding response to therapy.

主要目的是确定药物治疗是否 非那普利和或多沙佐星延迟或防止BPH的进展。 次要目标将包括评估的自然历史， BPH、最大尿流、症状评分和医疗结局。一个子群 的患者将接受超声、前列腺活检和血清激素检查。 为了确定BPH的组织病理学， 现有的生物标志物，其关于对 疗法